Patents by Inventor Hideto Morimoto

Hideto Morimoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11046751
    Abstract: Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: June 29, 2021
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Kenichi Takahashi, Aya Yoshioka, Hideto Morimoto, Masafumi Kinoshita
  • Publication number: 20200247872
    Abstract: Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.
    Type: Application
    Filed: April 10, 2020
    Publication date: August 6, 2020
    Inventors: Kenichi TAKAHASHI, Aya YOSHIOKA, Hideto MORIMOTO, Masafumi KINOSHITA
  • Patent number: 10654912
    Abstract: Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: May 19, 2020
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Kenichi Takahashi, Aya Yoshioka, Hideto Morimoto, Masafumi Kinoshita
  • Publication number: 20180244754
    Abstract: Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.
    Type: Application
    Filed: September 8, 2016
    Publication date: August 30, 2018
    Inventors: Kenichi TAKAHASHI, Aya YOSHIOKA, Hideto MORIMOTO, Masafumi KINOSHITA
  • Patent number: 9994641
    Abstract: Disclosed are a novel anti-human transferrin receptor antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 6 and 7 that can pass through the blood-brain barrier, a fusion protein comprising a protein necessary to be brought into function in the central nervous system and the antibody, and method of their production. The fusion protein comprises amino acid sequences of an anti-human transferrin receptor antibody that recognizes an amino acid sequence selected from the group consisting of SEQ ID NOs:1, 2, and 3, and of other protein that is bound thereto on the C-terminal side.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: June 12, 2018
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Hiroyuki Sonoda, Hideto Morimoto, Yuri Koshimura, Masafumi Kinoshita, Haruna Takagi, Yoshiko Yoshii
  • Publication number: 20160369001
    Abstract: Disclosed are novel anti transferrin receptor antibody that can pass through the blood-brain barrier, a fusion protein comprising a protein necessary to be brought into function in the central nervous system and the antibody, and method of their production. The fusion protein comprises amino acid sequences of an anti-human transferrin receptor antibody that recognizes an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, and 3, and of other protein that is bound thereto on the C- terminal side.
    Type: Application
    Filed: December 24, 2014
    Publication date: December 22, 2016
    Inventors: Hiroyuki SONODA, Hideto MORIMOTO, Yuri KOSHIMURA, Masafumi KINOSHITA, Haruna TAKAGI, Yoshiko YOSHII
  • Patent number: 5262666
    Abstract: A semiconductor device including a substrate, a semiconductor element formed on the substrate, a terminal formed on the substrate and electrically connected to the semiconductor element, and a protective resistor formed on the substrate and electrically connected between the semiconductor element and the terminal. The resistor is composed of a ferromagnetic magnetoresistive material including Ni alloy. The device may be extended to detect magnetism by adding a magnetoresistive element composed of a ferromagnetic magnetoresistive material including the same Ni alloy as for the protective resistor and deposited at the same time. The device is superior in an anti-noise characteristic and is integrated. Furthermore, the device for detecting magnetism is formed with a lower cost.
    Type: Grant
    Filed: February 10, 1992
    Date of Patent: November 16, 1993
    Assignee: Nippondenso Co., Ltd.
    Inventors: Yoshimi Yoshino, Hideto Morimoto, Kenichi Ao